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Summary
Objective: To investigate efficacy and safety of lamotrigine (LTG) versus carbama-
zepine (CBZ) or valproic acid (VPA) in newly diagnosed focal (FE) and idiopathic
generalised (GE) epilepsies in adolescents and adults.
Methods: Open-label randomised comparative multicentre 24-week monotherapy
trial in newly diagnosed epilepsy patients of 12 years of age. Patients with FE were
treated with LTG or CBZ, those with GE received LTG or VPA. The primary efficacy
variable was the number of seizure-free patients during study weeks 17 and 24.
Results: Two hundred and thirty-nine patients were included. One hundred and
seventy-six patients suffered from FE and 63 from GE. In the FE group, 88 patients
eachwere treated with CBZ or LTG. Ninety-four percent of the CBZ patients and 89% of
the LTG patients became seizure-free according to an intent-to-treat analysis (not
statistically different). The rate of patients discontinuing treatment due to adverse
events or a lack of efficacy was 19% with CBZ compared to 9% with LTG (not
statistically different).* Corresponding author. Tel.: +49 785184250; fax: +49 785184555.
E-mail address: bsteinhoff@epilepsiezentrum.de (B.J. Steinhoff).
1059-1311/$ — see front matter # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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598 B.J. Steinhoff et al.In the GE group, 30 patients received VPA and 33 LTG. During study weeks 17 and
24, 61% of the LTG patients and 84% of the VPA patients had become seizure-free (not
statistically significant). The drop-out rate due to lack of efficacy or adverse events
was 12% with LTG and 3% with VPA (not statistically different).
Conclusions: This study indicates that the effectiveness of LTG in focal and general-
ised epilepsy syndromes as initial monotherapy in patients12 years is in the range of
standard first-line antiepileptic drugs.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Only about 50% of patients with epilepsy achieve
adequate control following monotherapy with the
initial antiepileptic drug (AED).1 In order to avoid
insufficient efficacy or tolerability in newly-onset
epilepsy patients, AEDs with high effectiveness (high
retention rates) in various age groups and both focal
and generalised epilepsy syndromes would represent
a considerable progress in epilepsy therapy. Con-
trolled trials showing such effectiveness should be
used as evidence to determine whether an AED is
recommended as a first-line treatment for epilepsy.
In this context, lamotrigine (LTG) is a promising
candidate. Several studies comparing its effective-
ness in predominantly focal epilepsy (FE) syndromes
with standard first-line AEDs such as carbamazepine
(CBZ), phenytoin (PHT) and valproate (VPA)2—4
found that it may have advantages in special patient
groups, such as elderly patients.5 According to the
Veterans Administration studies, among the classi-
cal AEDs CBZ may be judged as the first-line therapy
in FE.6,7 If the effectiveness of LTG was similar or
better, one could argue that in special patient
populations in which potential drawbacks of CBZ
such as enzyme induction or sedating effects have
to be strictly avoided, LTG might be an alternative
and preferred in order to increase the probability of
a satisfying first AED treatment regimen.
In addition, it has been shown that LTG is effec-
tive in generalised epilepsy (GE) syndromes such as
idiopathic generalised epilepsies with absence,
myoclonic and generalised tonic-clonic seizures on
awakening2,3,8—10 without having specific drawbacks
which VPA as the leading AED in these indications
may have, i.e., weight gain or increased teratogenic
potential.4,11 In general, controlled studies are lack-
ing in adolescents both with FE and GE to demon-
strate the usefulness of LTG in this age group.
This study was therefore initiated to assess the
effectiveness of LTG in newly-onset FE and GE in
comparison with CBZ and VPA, respectively, as the
accepted standard AEDs and to perform a controlled
study in adolescent and adult patients. The clinical
conditions reflected the realities of everyday prac-
tice wherever possible.Materials and methods
This was an open-label randomised comparative
multicenter trial to assess the efficacy and toler-
ability of LTG compared to standard antiepileptic
drugs (AEDs) in newly diagnosed epilepsy patients of
12 years of age. At the time of the study, LTG was
only licensed for focal epilepsy syndromes. Patients
were recruited after unequivocal diagnosis of at
least one epileptic seizure and electroclinical or
imaging features indicating the onset of an epilepsy
syndrome requiring AED treatment. The study was
conducted in accordance with ICH-GCP guidelines
and the Declaration of Helsinki. Local authorities
and ethical committees of the participating 24 Ger-
man sites had accepted the study protocol. After
extensive information of patients and their legal
representatives in case of an age below 18 years,
written informed consent was obtained prior to
inclusion.
Patients with FE were randomised to an LTG or
CBZmonotherapy, whereas those with GE received a
monotherapy with LTG or VPA which reflects a com-
parison with the standard first-line AEDs in Germany
at the time of the study. Randomisation did not
consider distinct syndromes within the FE or GE
group. Thus, it was theoretically possible to have
a relative majority of certain epilepsy syndromes
within each subgroup treated by one or the other of
the study drugs.
In order to confirm the correct diagnosis and
epilepsy syndrome classification and thus the cor-
rect choice of the CBZ/LTG or the VPA/LTG treat-
ment arm, we included as a unique methodological
instrument that after recruitment of every patient
the key data (seizure classification, EEG data, age at
onset of the disease and syndrome classification)
were anonymously sent by FAX to one of the princi-
pal investigators (BJS for adult patients, MAU for
adolescent patients). Only if these principal inves-
tigators agreed with the syndrome classification,
were patients allowed to continue. Four patients
were excluded due to this additional assessment.
Eleven further patients were excluded from the
data analysis since they did not attend the following
study visits (n = 9), diagnosis of an epilepsy was not
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drug treatment was questioned after recruitment
(n = 1). Thus, the data of 239 of 254 patients could
be included in the final data analysis. Whole treat-
ment duration was 24  2 weeks. Efficacy, toler-
ability and safety were evaluated at regular visits
and by the additional use of a standardised toler-
ability questionnaire. In the event of a drop-out, a
final visit was performed, which was identical to
visit 4 at 24 weeks.
After randomisation of each subject, treatment
with LTG, CBZ or VPA was started according to the
German leaflet for each drug. LTG was distributed in
25 mg, 50 mg, 100 mg or 200 mg Lamictal1 tablets,
CBZ in the slow release form Timonil retard1 in
300 mg and 600 mg tablets (Desitin Arzneimittel
GmbH, Hamburg, Germany), and VPA as 150 mg,
300 mg and 600 mg Orfiril1 tablets (Desitin Arznei-
mittel GmbH). According to the German leaflet and
thus mandatory for the use in this study in adults and
adolescents of at least 12 years, LTG monotherapy
was started with 25 mg once a day for weeks 1 and 2
and then escalated to 50 mg once a day in weeks 3
and 4. From week 5 on, 100 mg once a day or 50 mg
b.i.d. were established. In monotherapy, a mainte-
nance dose of 100—200 mg was recommended. The
investigators were allowed to escalate the dose
further for clinical reasons up to a maximum of
500 mg. Similarly, they were allowed to titrate
the CBZ or VPA doses according to the German
leaflet. Thus, the CBZ preparation started with a
daily dose of 200—400 mg in adults and with 200—
300 mg in patients between 11 and 15 years. The
recommended maintenance dose was 600—1200 mg
in adults and 600—1000 mg in persons between 11
and 15 years. For VPA, a dose of 5—10 mg/kg body
weight was given initially and increased every 4—7th
day by approximately 5 mg/kg. The recommended
daily maintenance dose was 600—1200 mg for chil-
dren between 6 and 14 years or persons with a body
weight of 20—40 mg, 600—1500 mg for adolescents
from 14 years on or for persons with a body weight
between 40 and 60 kg, and 1200—2100 mg for adults
and persons weighing at least 60 kg. If clinically
necessary, investigators would have been allowed
to escalate CBZ and VPA further, individual toler-
ance provided.
The primary efficacy parameter was the percen-
tage of patients being seizure-free between treat-
ment weeks 17 and 24 on an intent-to-treat
calculation. Focal and generalised epilepsies were
analysed separately. In addition, we analysed the
overall retention rates exclusively based on lack of
efficacy or adverse events, the frequency of adverse
events and the tolerability according to the toler-
ability questionnaire we used.For the analysis of the primary efficacy end-
point logistic regression models were used: in the
subgroup of FE, the factors ‘treatment group’ and
a co-variable with the categories ‘Focal without
generalisation’ and ‘Focal with generalisation’
were included.
In the model for GE, three factors were used:
treatment group, age (<18, 18 years) and three
differing epilepsy syndromes (juvenile absence epi-
lepsy, juvenile myoclonic epilepsy, epilepsy with
generalised tonic-clonic seizures on awakening).
For time-to-event data like ‘‘leaving the study’’
methods of the survival analysis were applied.
Adverse event rates were compared by the Fisher’s
exact test.Results
Baseline demographic and clinical
characteristics
Out of 254 patients, 239 reached visit 1 and had
therefore received study treatment. These patients
were the subject of the data analysis. One hundred
and seventy-six patients suffered from FE and were
randomised to CBZ (n = 88) or LTG (n = 88). Sixty-
three patients suffered from GE and were rando-
mised to LTG (n = 33) or VPA (n = 30). At visit 4, 174
patients (78%) were still on trial medication. In the
FE group, median doses after 26 weeks were 900 mg
CBZ and 200 mg LTG in adults and 11.3 mg/kg CBZ
and 2.4 mg/kg LTG in adolescents. In the GE group,
the median doses were 1050 mg VPA (10.4 mg/kg in
adolescents) and 150 mg LTG (2.1 mg/kg in adoles-
cents). As shown in Table 1, the demographic base-
line distribution was equal within the GE and FE
treatment arms with a markedly lower age in the GE
group. Overall the proportion of adolescent patients
was small (14%) and higher in the GE group (n = 28;
44%). In the FE group, however, the rate of adoles-
cent patients was almost negligible (n = 5; 3%).
In the FE group, median doses at the end of the
study were 900 mg CBZ (mean 839.2  326.8; range
450—1800 mg) and 200 mg LTG (mean 170.6  58.2;
range 75—300 mg). In theGE group, themediandoses
were 1050 mg VPA (mean 1159.4  463.0; range
600—2100 mg) and 150 mg LTG (mean 155.9 
60.5; range 75—300 mg). Doses per bodyweight were
as follows: in the FE group, the median CBZ dose was
11.3 mg/kg (mean 11.44 4.04; range 5.1—19.7),
the median LTG dose was 2.4 mg/kg (mean
2.35  0.91; range 1.0—5.1). The corresponding fig-
ures in the GE group were 11.3 mg/kg (mean
14.17  5.64; range 9.0—24.4) for VPA and 2.4 mg/
kg (mean 2.98  1.65; range 1.5—7.4) for LTG.
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Table 1 Baseline demographic characteristics of patients (n = 239).
Treatment group Total
Focal epilepsy group (FE) Generalised epilepsy group
(GE)
Carbamazepine
(FE)
Lamotrigine
(FE)
Lamotrigine
(GE)
Valproate
(GE)
Sex
Male: n (%) 54 (61.4) 52 (59.1) 13 (39.4) 14 (46.7) 133 (55.6)
Female: n (%) 34 (38.6) 36 (40.9) 20 (60.6) 16 (53.3) 106 (44.4)
Total 88 88 33 30 239
Age (years)
Mean age  standard deviation 43.1  17.3 46.6  18.8 22.3  13.0 23.3  10.7 39.0  19.3
<18 Years: n (%) 1 (1.1) 4 (4.5) 14 (42.4) 14 (46.7) 33 (13.8)
18 Years: n (%) 87 (98.9) 84 (95.5) 19 (57.6) 16 (53.3) 206 (86.2)
Total no. of seizures during last
6 months prior to recruitment
mean
12.4  27.3,
median 3
mean
12.9  37.1,
median 3
mean
16.4  43.6,
median 2
mean
23.0  52.5,
median 2
mean
14.4  36.9,
median 3Efficacy
Seizure freedom
FE group
Between treatment weeks 17 and 24, 94.3% of the
CBZ patients (83/88) and 88.6% of the LTG patients
(78/88) were seizure-free during that last period of
the study. Eleven CBZ (12.5%) and 16 LTG patients
(18.2%) had experienced seizures during the titra-
tion phase but became seizure-free during the study
and particularly between study weeks 17 and 24. If
these titration phase patients are excluded, the
number of patients who stayed seizure-free during
the whole study period without seizures during the
titration phase was 72 (81.8%) with CBZ and 62
(70.5%) with LTG. The difference between the
CBZ and LTG groups was not statistically significant.
Table 2 summarises the data.
GE group
In the GE group, 83.3% of VPA patients (25/30)
became seizure-free compared to 60.6% of LTG
patients (20 of 33) (not significantly different) dur-
ing study weeks 17 and 24 (intent-to-treat basis).Table 2 Seizures in weeks 17—24, FE group.
No seizures between study weeks 17 and 24
No seizures between study weeks 17 and 24
but in earlier study phase
Seizure-free throughout the whole study period
TotalSeven LTG and six VPA patients suffered from sei-
zures during titration but became seizure-fee. The
marked, though not significant, difference between
VPA and LTG resulted from a superiority of VPA in a
special subgroup of patients with myoclonic sei-
zures, i.e., with juvenile myoclonic epilepsy
(JME): 10 patients in the LTG group (30.3%) and four
patients in the VPA group (13.3%) suffered from this
syndrome. Thirty percent of the patients treated
with LTG (n = 3) and 75% of the VPA patients (n = 3)
became seizure-free. Due to the small groups and
the imbalance of distribution, a statistical compar-
ison of this special subgroup was not performed.
Among GE patients without myoclonic seizures,
73.9% (17/23) with LTG and 84.6% with VPA (22/
26) became seizure-free.
Retention rates
Effectiveness of a treatment is mainly influenced by
efficacy and tolerability. It is measured by the
retention rate over the study period. Fig. 1a and
b shows the overall retention rates for CBZ and LTG
in the FE group and LTG and VPA in the GE group.
Seventeen patients (19%) stopped CBZ treat-
ment during the study compared to seven patientsTreatment group
Carbamazepine, n (%) Lamotrigine, n (%)
83 (94.3) 78 (88.6)
11 (12.5) 16 (18.2)
72 (81.8) 62 (70.5)
88 (100) 88 (100)
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Table 3 Withdrawals from study between study visit 1 (onset of medication) and final visit.
Antiepileptic drug and epilepsy syndrome Reason for withdrawal
Adverse
event (n)
Lack of
efficacy
(n)
Consent withdrawn
or lost to
follow-up (n)
Other
(n)
Total
withdrawals
(n)
Total
patients
(n)
Carbamazepine, focal epilepsy 17 0 7 5 29 88
Lamotrigine, focal epilepsy 7 1 13 3 24 88
Lamotrigine, generalised epilepsy 2 2 0 1 5 33
Valproate, generalised epilepsy 1 0 2 1 4 30(8%) who did not continue LTG in the FE group.
One additional LTG patient dropped out due to a
lack of efficacy which did not occur in the CBZ
group. Retention rates considering adverse eventsFigure 1 (a) Overall retention rates for CBZ and LTG in
the focal epilepsy group (n = 176) and (b) for VPA and LTG in
the generalisedepilepsy group (n = 63).Note that retention
rates drop markedly approximately from day 150 on. This
did not result from a late-onset lack of efficacy or adverse
events but from the fact that according to the study pro-
tocol (seeTable2) numerouspatientsdecided tohavevisit 4
up to 2 weeks earlier than scheduled and thereafter were
not followed anymore. trtgrp, treatment group.and lack of efficacy only were therefore 81% for CBZ
and 91% for LTG (not significant).
Two of the 33 LTG patients with GE discontinued
the study due to lack of efficacy. No VPA patient
withdrew for this reason. The patients who with-
drew LTGwere both non-responders with JME. With-
drawals due to adverse events occurred twice (rash)
in the LTG and once (hepatitis) in the VPA group.
Thus, retention rates considering adverse events
and lack of efficacy only, were 88% for LTG and
97% for VPA. Detailed figures for all patients who
withdrew prior to the last study visit are shown in
Table 3.
Adverse events
At least one adverse event occurred in 81 patients in
the CBZ group (91.0%) and in 68 patients in the FE
LTG group (77.3%). In the GE group, the matching
figures were 24 (72.7%) with LTG and 25 (83.3%) with
VPA.
Serious adverse events occurred in eight patients
in the CBZ group (9%), in six patients in the LTG FE
group (7%), in five patients in the LTG GE group (15%)
and in one patient in the VPA group (3%). However, in
order to judge the drug safety in an adequate
manner, it is more important to point out the drug
adverse reactions, i.e., the adverse events the
investigators suggested to be at least possibly
related with the study drug. Such adverse drug
reactions occurred in 65 (74%) of the CBZ patients,
in 38 (43%) of the LTG patients with FE, in 15 (45.5%)
of the LTG patients with GE, and in 16 (53%) of the
VPA patients. Table 4 shows the 10 most frequent
adverse drug reactions in each group.
Only under VPA a weight increase (mean 3.9 kg)
was observed after 24 weeks. However, this specific
side effect that was not apparent with CBZ or LTG
did not lead to discontinuation.
Adverse events leading to discontinuation of the
study drug and being judged as at least possibly
related with the AED treatment were rash or der-
matitis (n = 8; 9%), fatigue (n = 4; 5%), gait abnorm-
ality or ataxia (n = 2; 2%), depression (n = 1; 1%) and
hyponatremia (n = 1; 1%) under CBZ, rash (n = 7; 6%;
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Table 4 Five most frequent adverse drug reactions.a
Adverse drug reaction n (%)
Carbamaze pine (focal epilepsy group) (n = 88)
Fatigue 38 (43.2)
Amnesia 9 (10.2)
Pruritus 9 (10.2)
Erythematous rash 8 (9.1)
Thinking abnormal 7 (8.0)
Abnormal gait 7 (8.0)
Lamotrigine (focal epilepsy group) (n = 88)
Fatigue 13 (14.8)
Erythematous rash 5 (5.7)
Headache 5 (5.7)
Nausea 5 (5.7)
Nervousness 4 (4.5)
Sleep disorder 4 (4.5)
Pruritus 4 (4.5)
Alopecia 4 (4.5)
Dizziness 4 (4.5)
Lamotrigine (generalised epilepsy group) (n = 33)
Erythematous rash 4 (12.1)
Fatigue 3 (9.1)
Pruritus 3 (9.1)
Dizziness 3 (9.1)
Nervousness 2 (6.1)
Alopecia 2 (6.1)
Lamotrigine (both groups) (n = 121)
Fatigue 16 (13.2)
Erythematous rash 9 (7.4)
Dizziness 7 (5.8)
Pruritus 7 (5.8)
Nervousness 6 (5.0)
Valproate (generalised epilepsy group) (n = 30)
Increased appetite 7 (23.3)
Fatigue 5 (16.7)
Weight increase 5 (16.7)
Alopecia 3 (10.0)
Tremor 3 (10.0)
a Five most frequent adverse drug reactions (adverse events
the investigators suggested to be at least possibly related with
the study drug). If several adverse drug reactions occurred
equally often, they are quoted. In this case, more than five
adverse drug reactions are listed.both groups (n = 121)), fatigue, nausea and leuco-
penia (n = 1 each; 0.8%) under LTG and hepatitis
(n = 1; 3%) under VPA. Table 5 summarises the
adverse events leading to withdrawal of the study
drugs.Discussion
This study evaluated the efficiency of LTG versus
CBZ and VPA in FE and GE in a prospective compara-
tive study. LTG was an effective and well-toleratedtreatment for adolescents and adults with either FE
or GE. In comparison to standard AEDs such as CBZ or
VPA, LTG was similarly effective. We attempted to
reflect clinical practice as much as possible and to
escalate the dosage according to the German leaflet
and to clinical criteria so that seizures during titra-
tion did not necessarily lead to a discontinuation of
the study drug. It is apparent that during the initia-
tion of LTG treatment, seizure-related drop-outs
may occur more often due to the slow dose escala-
tion mandatory for LTG. We have to admit that most
probably a drop-out criterion ‘‘first seizure under
treatment’’ would have led to lower LTG retention
rates. However, the study shows that, under very
realistic treatment conditions, LTG is similarly
effective as CBZ in FE and as VPA in GE as suggested
by previous trials.2—4,8—10 However, these studies
were mainly either syndrome-specific but not com-
parative8,9 or they classified seizures but not syn-
dromes.2—4 In this study, we tried to classify the
underlying newly-onset epilepsy syndromes as pre-
cisely as possible by an additional control of the
correct diagnosis by two of the authors. In the
comparative trial between topiramate and CBZ or
VPA, which is a recently published study with a
similar design,12 the decision if the study drug
was compared to CBZ or VPAwas purely in the hands
of the local investigators so that a considerable
syndrome overlap between FE and GE was highly
probable. Syndrome-specific conclusions were
therefore not possible. In clinical practice, it may
be essential to get an impression how effective a
new drug may be in comparison with the gold stan-
dard. Thus, we feel confident in recommending the
study design described here to obtain essential
practical information in this respect. However, in
order to overcome the partially imbalanced distri-
bution of certain syndromes such as JME in our study,
one should consider additional randomization
according to such syndromes and hence a clearly
higher total number of patients still allowing statis-
tically relevant conclusions.
Since many more controlled clinical trials are
available that demonstrate the good efficiency of
LTG in FE, it is not surprising that the results of our
study underline these experiences.2,3 We could
confirm that LTG is less sedative than CBZ. Although
this led to slightly lower retention rates under CBZ,
in our study on adolescents and adults this trend
was less obvious than in other patient groups such
as elderly patients who are more susceptible for
sedating adverse events and in which statistically
significant advantages of LTG could be demon-
strated.5 However, the results of our study suggest
that LTG may be equally effective and a first-line
AED in patients in which the potential adverse
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Table 5 Adverse events leading to withdrawal.
Number Antiepileptic drug and
epilepsy syndrome
Adverse event Severitya Causal relationshipb
1 CBZ, focal epilepsy Rash Severe Almost certain
2 CBZ, focal epilepsy Hyponatremia Severe Probable
3 CBZ, focal epilepsy Rash Moderate Probable
4 CBZ, focal epilepsy Rash Moderate Almost certain
5 CBZ, focal epilepsy Abnormal gait Severe Almost certain
6 CBZ, focal epilepsy Fatigue Severe Almost certain
7 CBZ, focal epilepsy Surgical intervention Moderate Unrelated
8 CBZ, focal epilepsy Ataxia Moderate Almost certain
9 CBZ, focal epilepsy Rash Moderate Almost certain
10 CBZ, focal epilepsy Depression Moderate Possible
11 CBZ, focal epilepsy Fatigue Moderate Probable
12 CBZ, focal epilepsy Rash Moderate Probable
13 CBZ, focal epilepsy Rash Moderate Probable
14 CBZ, focal epilepsy Fatigue Moderate Probable
15 CBZ, focal epilepsy Dermatitis Severe Almost certain
16 CBZ, focal epilepsy Astrocytoma Severe Unrelated
17 CBZ, focal epilepsy Rash Severe Probable
18 LTG, focal epilepsy Rash Moderate Almost certain
19 LTG, focal epilepsy Nausea and diarrhea Severe Possible
20 LTG, focal epilepsy Headache Moderate Unlikely
21 LTG, focal epilepsy Rash Moderate Almost certain
22 LTG, focal epilepsy Rash Moderate Probable
23 LTG, focal epilepsy Leucopenia Severe possible
24 LTG, focal epilepsy Rash Moderate Almost certain
25 LTG, focal epilepsy Fatigue Severe Possible
26 LTG, focal epilepsy Tremor, muscle weakness Moderate Unlikely
27 LTG, focal epilepsy Rash Moderate possible
28 LTG, generalised epilepsy Rash Moderate Almost certain
29 LTG, generalised epilepsy Rash Severe Probable
30 VPA, generalised epilepsy Hepatitis Severe Possible
CBZ, carbamazepine; LTG, lamotrigine; VPA, valproate.
a Severity was classified as mild, moderate or severe.
b Causal relationship according to the Investigator’s opinion.event profile of CBZ or the possible results of its
strong enzyme-inducing properties are a major
drawback. In addition, we can add further informa-
tion that this is also true if slow-release CBZ is used
which was not the case in most of the previous
comparative trials. In the FE group, we were not
able to recruit enough adolescents in order to gain
clinically relevant information in this age group.
Our data did however not suggest specific disad-
vantages of either drug.
In GE, the good efficacy of LTG was recognised
early after its introduction and primarily described
in open case studies.9,13—21 Furthermore, it was
suggested that LTG might have advantages even in
patients with GE refractory to VPA or ethosuxi-
mide.22 The efficacy of LTG was also demonstrated
in placebo-controlled trials in relatively small
patient groups.8,10 These studies almost exclusively
included patients with absence epilepsies with
and without generalised tonic-clonic seizures orpatients with generalised tonic-clonic seizures as
the only seizure type. Some of the latter epilepsy
syndromes were most probably included in the com-
parative trials aiming primarily at FE and comparing
LTG with CBZ.2,3 A recent retrospective study in
idiopathic generalised epilepsy patients suggested
a superiority of VPA23 but naturally presented the
methodological problems every retrospective sur-
vey cannot prevent. The major drawback of this
study was certainly that the number of patients
treated with VPA as first-line AED was considerably
higher than the number of patients starting with LTG
so that a selection bias was highly probable.
In general, we have to admit that our data in GE
do not represent a satisfactory patient number for a
comprehensive statistical analysis. Nevertheless,
the group comparison showed no evidence for an
inferiority of LTG compared to VPA in patients with
GE with absence and generalised tonic-clonic sei-
zures. It may be important that these GE syndromes
604 B.J. Steinhoff et al.usually have a better therapy prognosis as JME and
that the rate of JME patients was considerably
higher in the LTG group. In general, it became
apparent that VPA is an excellent drug in general-
ised epilepsies, but also that LTG may be an eff-
ective and well-tolerated alternative, especially
if VPA-specific drawbacks such as teratogenic
effects11 or weight gain4 are major arguments for
the right AED decision.
As mentioned earlier, the rate of patients with
JME was considerably lower in the VPA arm in spite
of the initial randomization since we did not ran-
domise further according to distinct epilepsy syn-
dromes among the GE group. Our data may indicate
that within the small subgroup of patients with
myoclonic seizures VPA could be more effective.
They are certainly not appropriate to draw definite
conclusions concerning this question. Open studies
reported the beneficial effects of LTG in JME20,24,25
and sometimes claimed superiority over VPA.26 This
is further supported by a recent open study that
demonstrated that in almost half of 63 patients
with JME, an unsatisfactory course with VPA could
be successfully switched to LTG monotherapy.27 On
the other hand, reports on the occasional specific
exacerbation of myoclonic seizures in JME under
the influence of LTG do exist.25,28 Furthermore, in
severe myoclonic epilepsy of infancy the increase
of myoclonic seizures was reported repeat-
edly.29,30 Consequently, the responder rates of
patients with generalised myoclonic seizures
according to open studies vary widely from 29%
to 93%.31 More data of controlled trial addressing
this open and clinically relevant question are
strongly recommended. We want to emphasise that
the use of VPA as comparator in the GE group does
not mean that VPA is not an established option in
focal epilepsy syndromes as well. The value of VPA
for the monotherapy of focal epilepsy syndromes is
unquestionable.7 Our study design just used the
established first-line AED for focal (CBZ) and gen-
eralised (VPA) epilepsy syndromes in Germany at
the time of trial.
Our study emphasises that LTG as the first mono-
therapy is equally effective and well tolerated in
adolescent and adult patients with FE and GE.
Furthermore, LTG was less sedative than CBZ and
not associated with the problem of weight gain,
which was specifically apparent with VPA. These
findings suggest that the profile of LTG indicates
specific patient populations inwhomonemay suggest
to prefer LTG if AED treatment has to be initiated.
Observations of longer treatment durations than the
24 weeks duration in our trial are necessary to eval-
uate better the advantages and disadvantages of
each AED under practical conditions.Finally, we believe that the main and somewhat
very encouraging finding of this study is that we
did not find any particular difference between the
three tested AEDs concerning any of the outcome
measures and that therefore CBZ, VPA and LTG are
equivalent in their effectiveness. CBZ and VPA
proved to be very favourable options. We conclude
that LTG is an important additional treatment
possibility as monotherapy both in focal and gen-
eralised treatments and may be considered as
potential first-line AED if the individual patient’s
profile requires to avoid disadvantages resulting
from specific properties such as potent enzyme
induction or the possible induction of weight gain.Acknowledgments
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